文献速递男科与性医学

复发性缺血性阴茎异常勃起的药物治疗:分子治疗综述与新的临床管理范式

Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm.
PubMed 文献 · BJU Int · 2021-03-28

靶向神经血管、激素和血液学机制的药物展现出治疗前景,作者据此提出阶梯式临床管理方案,并指出RIP仍是被医学忽视的疾病,当前管理侧重急性期处理而非疾病病程调控。

要点

  • 靶向神经血管、激素和血液学机制的药物对RIP有治疗前景
  • 提出按不同机制方向实施药物的阶梯式临床管理方案
  • 当前RIP管理侧重急性期处理,缺乏标准化临床路径

核心结论

  • RIP仍是被医学忽视的疾病,当前管理聚焦急性状态处理而非调控疾病病程。
  • 持续研究RIP分子机制并建立标准化临床路径可改善患者照护质量。

研究设计与样本

  • 评估RIP医学管理与分子病理生理的临床前及临床研究,并按研究质量与患者结局评价病例系列和随机试验以确定临床管理方案。

主要发现

  • 近期研究加深了对RIP潜在分子病理生理的理解,为开发新治疗药物铺路。
  • 靶向RIP相关神经血管、激素和血液学机制的药物展现出解决该病症的较大希望。
  • 多种作用于不同机制方向的治疗药物可按临床管理方案实施,以潜在优化RIP结局。

临床怎么用

  • 可按神经血管、激素和血液学等不同机制方向选择药物,并依据提出的阶梯式临床管理方案实施以潜在优化RIP结局。
  • 临床管理不应仅局限于急性期处理,应关注疾病病程调控并推动标准化临床路径。

局限性

  • RIP仍是医学上被忽视的疾病,当前管理侧重急性状态处理而非调控疾病病程。
  • 需持续研究RIP分子机制并建立标准化临床路径以改善照护质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine the current molecular therapeutics in the medical treatment of recurrent ischemic priapism (RIP). To propose a stepwise clinical management paradigm for the treatment of RIP. METHODS: We performed a literature search using the PubMed database for the terms 'recurrent ischemic priapism' and 'stuttering priapism' up until December 2020. We assessed pre-clinical and clinical studies regarding medical management of RIP and molecular pathophysiology. Case series and randomized trials were evaluated by study quality and patient outcomes to determine a potential clinical management scheme. RESULTS: Recent research has fostered an improved understanding of the underlying molecular pathophysiology of RIP that has paved the way forward for developing new therapeutic agents. Medications targeting neurovascular, hormonal and haematological mechanisms associated with RIP show great promise towards remedying this condition. A host of therapeutic agents operating across different mechanistic directions may be implemented according to a clinical management scheme to potentially optimize RIP outcomes. CONCLUSION: RIP remains a medically neglected condition with current management focused on treating the acute condition rather than modulating the course of disease. Continued research into the molecular mechanisms of RIP and standardized clinical pathways can improve the quality of care for patients suffering from this condition.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Joice GA, Liu JL, Burnett AL, et al. Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm. BJU Int. 2021. PMID: 33606327. doi:10.1111/bju.15370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。